Dialysis industry news

Stories from the dialysis comunity across the globe.



Statins Lower Mortality Risk After CABG - Renal and Urology News PDF Print
June 08, 2015 Statins Lower Mortality Risk After CABG - Renal and Urology News
Patients taking a statin had lower mortality risk in weeks after the surgery, researchers say.

(HealthDay News) -- Statin use may lower mortality in the weeks and months after coronary artery bypass graft surgery, according to a study presented at the annual meeting of the European Society of Anaesthesiology.

The new study was based on data involving more than 16,000 British patients. All were at least 40 years old at the time they underwent coronary artery bypass graft surgery, and the researchers tracked outcomes at 1 month and 6 months after the surgery. 

Apart from statins, many of the patients had been taking a broad range of other types of cardiovascular medications prior to the surgery. For example, nearly three-quarters were taking ?-blockers, more than 60% were taking angiotensin converting enzyme inhibitors, and nearly 45% were taking calcium channel blockers.

However, after conducting 5 statistical analyses, the team found that only the use of statins was tied with a significant protective effect in reducing a patient's postoperative mortality risk. This finding remained even after the researchers factored in each patient's prior history of other chronic illnesses. Simvastatin was tied to the most significant drop in postoperative mortality risk (a 77% decline).

The study was led by Robert Sanders, Ph.D., an assistant professor of anesthesiology at the University of Wisconsin in Madison. His team of U.S. and U.K. researchers noted that the vast majority of patients included in the analysis -- roughly 85% -- were already routinely taking a statin before their heart surgery. "The unknown is why the other 15% were not on statins," Sanders told HealthDay. Some may have had an intolerance to the medications or adverse effects, while others might simply not have been offered the cholesterol drug by their physicians, he noted.

...

 
DaVita HealthCare Partners Inc (NYSE:DVA)'s Co-Chairman of the Board Robert ... - OctaFinance.com PDF Print

DaVita HealthCare Partners Inc (NYSE:DVA)'s Co-Chairman of the Board Robert ... - OctaFinance.com

Robert Margolis Insider Sell Transaction

Considering the transaction Robert Margolis made he is in the insider trades focus today. The Co-Chairman of the Board of DaVita HealthCare Partners Inc (NYSE:DVA) 81.92 -0.62 -0.75% and an insider, unloaded 31,400 shares worth $2,618,461 U.S Dollars. The average price was $83.4 per share. In the last month, he also unloaded 31,400 shares worth about $2,597,829 USD. The date of trade was June 5, 2015, and it was revealed in a SEC-filed Form 4, which you can locate here. The probability of this sell staying unseen is super low as it’s significant, with Robert Margolis now having rights to 2.45 million shares – that is 1.14% of the company’s total market cap.

Davita Healthcare Partners Inc Stock Rating, Sentiment and Fundamentals

Because the insider transaction is symbolic, it might mean that Robert is a pessimist regarding Davita Healthcare Partners Inc’s stock worth. According to the fifteen analysts that are covering this company’s financial reports, there is an expectation of earnings for every share of $3.77 for the 2015 year, which gives Davita Healthcare Partners Inc a Price to Earnings ratio of 21.89. Furthermore, an earnings-per-share growth rate year-on-year of 12.50% is expected. Apparently he is not the only one. The stock market seems to agree given the Bulls / Bears Sentiment Index is 0.92 according to Psychsignal.

* Read How Our Stock Ratings System Works

Our analysts place NEUTRAL rating on the stock based on our trend-following model which is depicted below. Davita Healthcare Partners Inc’s share price is still trending upward from the last 200 days, during which it has risen by 11.84%.

Price Chart of Davita Healthcare Partners NYSE:DVA Stock

DaVita HealthCare Partners Inc (NYSE:DVA)'s Co-Chairman of the Board Robert ... - OctaFinance.com

Source: RightEdgeSystems, Yahoo Split & Dividend Adjusted Data and OctaFinance Interpretations

Well-known stock market traders such as Ray Dalio have often claimed that the best returns are made through fundamental and technical analysis. This is definitely not the case with this company.

Hedge Funds Ownership

SEC filings showed that, 468 institutional players had shares of Davita Healthcare Partners Inc. Octafinance tracked institutional and hedge funds have traditionally had a very high interest in Davita Healthcare Partners Inc’s stock, and that was also the case in the last quarter. The institutional ownership was 197.83% of the stock’s outstanding shares. They increased by 249.27 million the total shares they hold. As of that quarter these institutional and hedge funds owned 425.33 million shares. A total of 31 funds closed their positions in Davita Healthcare Partners Inc and 156 reduced their holdings. There were 56 funds that created new positions and 187 funds that added to their positions.

This company is Top 10 in 16 of them. These are: Foundation Asset Management Lp, Swift Run Capital Management Llc, Summit Partners L P, Timessquare Capital Management Llc, Cognios Capital Llc, Triple Frond Partners Llc, Hikari Power Ltd, Gates Capital Management Inc., Hikari Tsushin Inc., Roundview Capital Llc.

HEDGE-FUNDS-LIST-DATABASE-FREE Bluestein R H & Co had the greatest investment with ownership of 10,650 shares as of Q4 2014 for 0.05% of the fund’s portfolio. Dock Street Asset Management Inc is another bullish asset manager having 57,383 shares of the company or 2.29% of their stocks portfolio. The stock is also 1.06% of the fund’s AUM. In addition First Republic Investment Management Inc. have 0.01% of their stock portfolio invested in the company’s market cap for 7,274 shares. The Massachusetts-based fund Foster Dykema Cabot & Co Inc Ma revealed it had acquired a stake worth 2.05% of the fund’s stock portfolio in Davita Healthcare Partners Inc. The Illinois-based fund Geneva Advisors Llc is also positive about the Colorado-based company, owning 5,435 shares or 0.01% of their stock portfolio.

DaVita HealthCare Partners NYSE:DVA Company Profile

Davita Healthcare Partners Inc

DaVita HealthCare Partners Inc. consists of two divisions, Kidney Care and HealthCare Partners (HCP). Kidney Care is a provider of dialysis services in the United States, treating patients with chronic kidney failure and end stage renal disease (ESRD). Kidney Care division develops innovative clinical care, offers integrated treatment plans, personalized care teams and health-management services. As of December 31, 2014, we provided dialysis and administrative services in the U.S. through a network of 2,179 outpatient dialysis centers in 46 states and the District of Columbia, serving a total of approximately 173,000 patients. HealthCare Partners division is a patient- and physician-focused integrated health care delivery and management company. HealthCare Partners manages and operates medical groups and affiliated physician networks in Arizona, California, Nevada, Florida and New Mexico. As of December 2014, HealthCare Partners had approximately 837,000 members under its care.

Company Website: DaVita HealthCare Partners

Today its market cap is: $17.75 billion and it has 214.89 million shares outstanding. The company has 57900 employees. Today the company has 86.62% shareholders and the institutional ownership stands at 86.62%. Davita Healthcare Partners Inc was formed in Delaware on 1994-04-04. The stock closed at $82.54 yesterday and it had average 2 days volume of 246995 shares. It is up from the 30 days average shares volume of 243342. Davita Healthcare Partners Inc has a 52w low of $69.83 and a 52 weeks high of $85.17. The current price is above the 200 days SMA. Davita Healthcare Partners Inc last issued its quarterly earnings report on 05/04/2015. The company reported 0.86 EPS for the quarter, above the consensus estimate of 0.85 by 0.01. The company had a revenue of 3.29 billion for 3/31/2015 and 3.33 billion for 12/31/2014. Therefore, the revenue was -40,052,000 down.

* The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 18 – 2014.

* Represents the weighted average sale price of $83.7702. The range of prices for the sale of these shares was $83.59 – $83.94 – rounded to the nearest hundredths. The reporting person undertakes to provide upon request by the Commission staff – the Issuer – or a security holder of the Issuer – information regarding the number of shares purchased or sold at each separate price.

* Represents the weighted average sale price of $82.8881. The range of prices for the sale of these shares was $82.46 – $83.45 – rounded to the nearest hundredths. The reporting person undertakes to provide upon request by the Commission staff – the Issuer – or a security holder of the Issuer – information regarding the number of shares purchased or sold at each separate price.

* The shares were sold by Robert and Lisa Margolis Family Trust – 7/27/2000.

* Represents the weighted average sale price of $83.5757. The range of prices for the sale of these shares was $83.46 – $83.79 – rounded to the nearest hundredths. The reporting person undertakes to provide upon request by the Commission staff – the Issuer – or a security holder of the Issuer – information regarding the number of shares purchased or sold at each separate price.

* The shares are held by Margolis Family GST Exempt Trust – 12/11/2012.

...

 
Risk Factors for UTI Recurrence and Renal Scarring in Kids - Medscape PDF Print
Medscape
VUR occurs in 30% to 40% of children who have had a UTI and is also linked to renal scarring. Bladder and bowel dysfunction may also predispose to recurrent UTI and refers to problems filling or emptying the bladder and abnormal bowel patterns ...
Pediatric vesicoureteral reflux, bowel/bladder dysfunction increase recurrent

...

 
MERS CoV Infection in Two Renal Transplant Recipients: Case Report - Medscape PDF Print

MERS CoV Infection in Two Renal Transplant Recipients: Case Report
Medscape
Middle East Respiratory Syndrome Coronavirus (MERS CoV) infection has recently emerged as a cause of severe potentially fatal pneumonia. The clinical presentation ranges from asymptomatic infection to severe pneumonia and acute renal failure. Data on ...

and more »

...

 
The Long-term Outcomes of Systemic Vasculitis - Medscape PDF Print

The Long-term Outcomes of Systemic Vasculitis
Medscape
Patients with generalized ANCA-associated small vessel vasculitis (AAV) have a very poor outcome if the ANCA-associated vasculitis is not diagnosed, evaluated and treated properly. The introduction of treatment with immunosuppressive therapy has ...

...

 
<< Start < Prev 171 172 173 174 175 176 177 178 179 180 Next > End >>

Page 176 of 4210
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.